ADULT AIDS CLINICAL RESEARCH

梅哈里医学院和范德比尔特大学的医学院 大学联合提议将艾滋病临床试验单位设在 田纳西州纳什维尔。此应用程序的主要目标是 成功地在艾滋病毒感染者身上进行临床试验；改善 将代表性不足的人群纳入这些试验；改善 年中南部地区人们获得实验性疗法的机会 国家；并调查两国之间的差异和独特方面 这一地理区域的艾滋病毒感染。这一合作努力是 可行的原因如下：1)田纳西州中部和中部 南方正在经历艾滋病毒感染的快速增加。这 人口在ACTG试验中基本上没有代表性，也没有机会参加 因此，目前存在大量潜在的临床试验 参与者。2)Meharry医学院，有能力招生 在少数民族中有效地以文化敏感的方式 社区，可以为整个委员会作出独特的贡献。3) 范德比尔特大学在临床研究和临床研究方面的长期记录 在艾滋病毒临床试验方面的经验将是Meharry的一个子单元 ACTU并在开发、实施和实施方面提供专业知识 ACTG方案的。4)Meharry拥有目前唯一运营的CRC 在一家少数民族医疗机构。综合临床研究中心 范德比尔特的(GCRC)是世界上规模最大、最成功的 国家。因此，这一提议为两人提供了一个理想的机会 CRC将在临床试验中进行合作。

The medical faculties at Meharry Medical College and Vanderbilt University jointly propose an AIDS Clinical Trials Unit to be located in Nashville, Tennessee. The major goals of this application are to successfully perform clinical trials in HIV-infected persons; to improve inclusion of underrepresented populations in these trials; to improve access to experimental therapies for people in the mid-South region of the country; and to investigate the differences and unique aspects of HIV-infection in this geographic area. This collaborative effort is feasible for the following reasons: 1) Middle Tennessee and the mid- South are experiencing a rapid increase in HIV infection. This population has essentially no representation in nor access to ACTG trials at present thus representing a large pool of potential clinical trial participants. 2) Meharry Medical College, with its ability to recruit effectively and in a culturally sensitive manner in the minority community, can make a unique contribution to the ACTG as a whole. 3) Vanderbilt University with its long track record in clinical research and experience in clinical trials in HIV will be a subunit of the Meharry ACTU and lend expertise in the development, implementation, and conduct of the ACTG protocols. 4) Meharry has the only CRC currently operating in a minority health institution. The General Clinical Research Center (GCRC) at Vanderbilt is the largest and one of the most successful in the country. this proposal thus provides an ideal opportunity for the two CRC's to collaborate in clinical trials.